Why Delay Sublocade™? Experiences with Inpatient Buprenorphine ER Injections

Hosted by the Substance Use Disorder SIG

Sublocade™ (buprenorphine ER subcutaneous injection) is currently FDA approved for opioid use disorder following 7 days of a transmucosal buprenorphine product. For opioid use disorder (OUD) patients admitted to the hospital, discussing OUD management and providing a long acting management option prior to discharge may help increase medication assisted therapy clinic retention rates. However, implementing such a program has several potential barriers.

Objectives:

1. Describe potential benefits of administering inpatient buprenorphine ER injections
2. Identify potential challenges of administering inpatient buprenorphine ER injections

Speakers:

Andrew Merker
Associate Professor
Midwestern University College of Pharmacy Downers Grove